Have come here after a recommendation from a...

Have come here after a recommendation from a colleague.

Welcome.

Interesting thread. I'll need to spend some time studying this as I don't understand yet how the bisantrene drug is being positioned in the modern paradigm and am unfamiliar with the evidence for this drug.

The Triangle Report should help clear this up. See original post for link.

Is it really "cardioprotective" outside in vitro/animal studies? Or is it that it's just less toxic than standard athracyclines

There is evidence to suggest it is not just less cardiotoxic, but also cardioprotective. Is there direct evidence looking at cardioprotection in a clinical trial? No. Race will be starting the trial this year once RC220 is ready to go.

There is historic clinical evidence of a lack of cardiotoxicity in combination with cardiotoxic drugs, as well as the recent Phase 2 in Israel as ma420 mentioned. Combine this with the preclinical work done by Race.

Things have moved on substantially in the 30-40 years since the phase3 breast cancer trial referred to on the company website, the drug came out quite a bit worse for response rate against doxorubicin but no cases of heart failure it's true. But then better screening for risk , newer markers, availability of echocardiography etc and newer drugs like the liposomal anthracyclines (less cardiotoxic) may have changed the landscape.

It doesn't need to beat doxorubicin as a single agent. Will it make doxorubicin work better, and will it protect the heart from it? Looking likely.

Meant to add this link, 2023 paper om anthracycline induced cardiotoxicity - "are we about to clear this hurdle".Sadly no mention in here of bisantrene.https://www.ejcancer.com/article/S0959-8049(23)00113-2/fulltext

If bisantrene was mentioned the cat would be out of the bag. Putting the puzzle pieces together early is where opportunity is.